Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacodynamic evaluation of YKP3089 in epilepsy patients with a photo-induced paroxysmal EEG [electroencephalography]-response: proof of principle.

Next Previous
Trial Profile

Pharmacodynamic evaluation of YKP3089 in epilepsy patients with a photo-induced paroxysmal EEG [electroencephalography]-response: proof of principle.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cenobamate (Primary)
  • Indications Epilepsy
  • Focus Proof of concept; Therapeutic Use
  • Sponsors SK Life Science

Most Recent Events

  • 10 Jul 2019 Results assessing the effect of cenobamate on the IPS-induced EEG PPR in patients with photosensitive epilepsy published in the Neurology
  • 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology
  • 12 Jun 2012 Actual patient number is 11 as reported by ClincialTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top